NuVision is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma.
The USP of NuVision is that we were formed from, and are supported by, a world leading corneal research group whose aim is to address key clinical challenges to provide solutions to sight saving problems. This is the UK’s first ophthalmic biotech, backed by such a prestigious academic research group.
The company’s launch product is Omnigen, a biological wound dressing which aids the regeneration and healing of the surface of the eye. Omnigen is a ‘first of its kind’ human amniotic membrane-derived dry preserved biological matrix intended for ocular surface surgical and trauma therapy.
The founder of NuVision, Dr Andrew Hopkinson is the Principal Research Fellow in Academic Ophthalmology within the Division of Clinical Neuroscience at the University of Nottingham.
The business is co-owned by the founders, Dr Andrew Hopkinson (CEO), Professor Harminder Dua (Clinical Director), the directors Mr Bryan Lister (COO), Dr Helen Shaw (Chairman) and the University of Nottingham.